Precision BioSciences to Present at the European Society of Gene & Cell Therapy (ESGCT) 29th Congress
- Oral and Poster Presentations to Highlight Preclinical Research for ARCUS® Gene Editing DURHAM, N.C. --(BUSINESS WIRE)--Oct. 11, 2022-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage…
Precision BioSciences to Participate in Upcoming Jefferies Cell & Genetic Medicine Summit
DURHAM, N.C. --(BUSINESS WIRE)--Sep. 22, 2022-- Precision BioSciences, Inc. (Nasdaq: DTIL) a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene…
Precision BioSciences to Participate in Upcoming H.C. Wainwright 24th Annual Global Investment Conference
DURHAM, N.C. --(BUSINESS WIRE)--Sep. 7, 2022-- Precision BioSciences, Inc. (Nasdaq: DTIL) a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene…
Precision BioSciences Announces Senior Leadership Organizational Changes
DURHAM, N.C. --(BUSINESS WIRE)--Sep. 2, 2022-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene…
Precision BioSciences Reports Second Quarter 2022 Financial Results and Provides Business Update
- Launched Exclusive In Vivo Gene Insertion Collaboration with Novartis to Develop Single ARCUS Nuclease as Potential One-time Hemoglobinopathy Treatment - Extended Cash Runway to End of 2024 -…
Precision BioSciences to Report Second Quarter 2022 Financial Results on August 8, 2022
DURHAM, N.C. --(BUSINESS WIRE)--Aug. 1, 2022-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene…
Precision BioSciences Announces Closing of Underwritten Offering of Common Stock
DURHAM, N.C. --(BUSINESS WIRE)--Jun. 27, 2022-- Precision BioSciences, Inc. (Nasdaq: DTIL) (the “Company”), a clinical stage gene editing company developing ARCUS-based ex vivo allogeneic CAR T and…
Precision BioSciences Announces $50 Million Offering of Common Stock
DURHAM, N.C. --(BUSINESS WIRE)--Jun. 21, 2022-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS-based ex vivo allogeneic CAR T and in vivo gene…
Precision BioSciences Announces In Vivo Gene Editing Collaboration with Novartis to Develop Potentially Curative Treatment for Disorders Including Sickle Cell Disease
- Precision to Receive $75 Million Upfront for a Single Target; Precision Eligible to Receive up to an Additional $1.4 Billion in Milestones and Tiered Royalties on Sales of Licensed Products -…
Precision BioSciences Provides Update on Allogeneic CAR T Programs and Path Forward with Its Lead PBCAR0191 Candidate for CAR T Relapsed Patient Population
PBCAR0191 Achieved 100% Response Rate (ORR), 73% Complete Response (CR) Rate and 50% Durable Response Greater than Six Months Among Evaluable CAR T Relapsed Subjects PBCAR0191 Achieved Peak CAR T…
Precision BioSciences to Provide an Update on its Ongoing Allogeneic CAR T Programs via Hosted Virtual Webcast and Conference Call on Wednesday, June 8, 2022
DURHAM, N.C. --(BUSINESS WIRE)--Jun. 3, 2022-- Precision BioSciences, Inc. (Nasdaq: DTIL) a clinical stage gene editing company developing ARCUS ® -based ex vivo allogeneic CAR T and in vivo gene…
Precision BioSciences to Participate in Upcoming Jefferies Healthcare Conference
DURHAM, N.C. --(BUSINESS WIRE)--Jun. 3, 2022-- Precision BioSciences, Inc. (Nasdaq: DTIL) a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene…